Legal Status Overview
Gray AreaIndiana has no peptide-specific or 'research chemical'-specific statute; peptides fall under the general framework that governs any unapproved drug sold or compounded in the state. The Indiana Board of Pharmacy regulates drug sales and compounding practice under IC 25-26-13 and enforces USP compounding chapters (795/797/800/825), and it can declare new 'synthetic drugs' Schedule I substances under IC 25-26-13-4.1, but peptides like BPC-157 or TB-500 have not been placed in that synthetic-drug/controlled-substance category. Because these peptides are unapproved new drugs under federal law, whether a peptide can lawfully be sold, prescribed, or compounded in Indiana turns on the federal FDA 503A/503B compounding-bulk-substance lists and the FD&C Act's new-drug-approval requirement, not on any distinct Indiana rule.
Key Points
- Indiana has no statute or Indiana Administrative Code (856 IAC) rule that names 'peptides' or 'research chemicals' as a distinct regulated category, based on searches of Indiana Board of Pharmacy rules and code. [1]
- The Indiana Board of Pharmacy has general statutory authority under IC 25-26-13-4 to regulate the sale of drugs and devices in Indiana and to impound or embargo drugs, chemicals, or devices it deems unfit for use or dangerous to public health. [1]
- The Indiana Board of Pharmacy can adopt emergency rules under IC 25-26-13-4.1 declaring a new substance a 'synthetic drug' and thereby a Schedule I controlled substance under IC 35-48-2-4(d)(35), but this synthetic-drug mechanism has been used for compounds like synthetic cannabinoids and not for research peptides such as BPC-157 or TB-500. [2]
- The Indiana Board of Pharmacy adopted an interim rule incorporating the updated USP Chapters 795, 797, 800, and 825 sterile and non-sterile compounding standards, which is the general compounding-practice rule that would apply to any Indiana 503A pharmacy compounding a peptide, but this rule does not mention peptides by name. [3]
- Under the federal FDA compounding framework that Indiana pharmacies must follow, BPC-157 was placed on FDA's Category 2 safety-concern bulk-substance list in 2023 and was removed from Category 2 on April 15, 2026, but removal from Category 2 is not the same as Category 1 approval, so 503A pharmacies still cannot lawfully compound BPC-157 for human use even in Indiana. [4]
- BPC-157 and most other research peptides are classified by federal authorities as unapproved drugs that cannot be legally prescribed or sold over the counter anywhere in the United States, including Indiana, because they are absent from the FDA's Approved Drugs database. [5]
- A person in Indiana can legally obtain a peptide only through the same narrow federal pathways available nationwide, i.e. an FDA-approved product prescribed by a licensed practitioner (as with semaglutide/tirzepatide brand-name GLP-1 drugs) or a 503A/503B compounded preparation limited to substances on FDA's Category 1 or 503B bulk-substance lists, since Indiana imposes no separate, more permissive or more restrictive state-specific peptide import/personal-use rule. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
- No Indiana-specific legislative bill, Board of Pharmacy bulletin, or Attorney General guidance document specifically addressing peptides, research chemicals, or compounded semaglutide/tirzepatide was found in searches covering the last several years, indicating Indiana currently regulates this area only through its general pharmacy, controlled-substances, and compounding statutes referenced above. [3]
Peptide-by-peptide status in Indiana
| BPC-157 | BPC-157 is not FDA-approved and cannot lawfully be prescribed, sold over the counter, or compounded by an Indiana 503A pharmacy for human use, because it remains outside Category 1 of FDA's compounding bulk-substance list even after being removed from the Category 2 safety-concern list in April 2026, and Indiana has no separate rule making it more or less available. [4] |
|---|---|
| TB-500 (Thymosin Beta-4) | TB-500 has no Indiana-specific rule and, like BPC-157, is treated as an unapproved research peptide under the general federal FDA new-drug-approval framework that governs its sale and compounding in Indiana. |
| Semaglutide / Tirzepatide (GLP-1 class) | Brand-name semaglutide and tirzepatide products are lawful prescription drugs in Indiana when FDA-approved and prescribed by a licensed practitioner, while compounded versions of these drugs made outside the FDA's 503A/503B bulk-substance and shortage rules are subject to the same federal compounding restrictions that apply to Indiana pharmacies generally. [3] |
| Human Growth Hormone (HGH/somatropin) | Somatropin (HGH) is a federally controlled prescription drug under the Anabolic Steroids Control Act framework and Indiana's Uniform Controlled Substances Act (IC 35-48), so distributing or possessing it in Indiana without a valid prescription is unlawful under the same controlled-substances law that applies statewide, though no Indiana-specific HGH rule beyond that general framework was located. [2] |
Sources
Last researched: 2026-09-09
Frequently asked questions
Can I buy peptides like BPC-157 in Indiana without a prescription?
No, buying BPC-157 or similar research peptides without a prescription is not lawful in Indiana because these compounds are unapproved drugs under federal law that cannot be legally sold over the counter anywhere in the U.S., and Indiana has no separate rule creating an exception. [5]
Is it legal to import or travel with peptides into Indiana for personal use?
There is no Indiana-specific personal-import or travel allowance for research peptides; because BPC-157-type peptides are unapproved new drugs, bringing them into Indiana for non-prescribed personal use falls outside any lawful pathway under the general federal framework Indiana defers to.
Can an Indiana telehealth provider legally prescribe peptides like BPC-157?
An Indiana telehealth or in-person provider generally cannot lawfully prescribe BPC-157 for routine patient care because it does not qualify as an approved drug, an off-label use, or a lawfully compoundable substance under either 503A or 503B, a federal restriction that applies equally in Indiana. [4]
What penalties could someone face for selling unapproved peptides in Indiana?
Selling unapproved peptides in Indiana can expose a seller or clinic to Indiana Board of Pharmacy license discipline (probation, fines, suspension, or revocation) under its general statutory powers, plus federal FDA/FTC enforcement, since Indiana has no distinct peptide-penalty statute separate from its general drug-sale enforcement authority. [1]
Are compounded semaglutide or tirzepatide products legal in Indiana?
Compounded semaglutide/tirzepatide products can be lawful in Indiana only when prepared by a properly licensed 503A or 503B facility following FDA bulk-substance and shortage rules and Indiana's adopted USP compounding standards; outside those conditions, such compounded GLP-1 products are not legally sold in Indiana any more than in other states. [3]